Since the first culture of Helicobacter pylori 20 years ago, the diagnosis and treatment of upper gastroduodenal disease have changed dramatically. Peptic ulcer disease is now approached as an infectious disease, in which elimination of the causative agent cures the condition. The role of H. pylori infection in gastric cancers is increasingly recognized, and its role in other diseases of the upper gastrointestinal tract is being evaluated. Enormous progress has been achieved in determining the pathogenesis of this infection. Effective antimicrobial therapy is available, although there is still no ideal treatment, and indications for therapy continue to evolve. This review surveys scientific knowledge concerning H. pylori and focuses on the many aspects of this infection that are relevant to the clinician.
Epidemiology and Transmission
Infection with H. pylori occurs worldwide, but the prevalence varies greatly among countries and among population groups within the same country. 1 The overall prevalence of H. pylori infection is strongly correlated with socioeconomic conditions. 2 The prevalence among middleaged adults is over 80 percent in many developing countries, as compared with 20 to 50 percent in industrialized countries. The infection is acquired by oral ingestion of the bacterium and is mainly transmitted within families in early childhood. 1, 3 It seems likely that in industrialized countries direct transmission from person to person by vomitus, saliva, or feces predominates; additional transmission routes, such as water, may be important in developing countries. 4, 5 There is currently no evidence for zoonotic transmission, although H. pylori is found in some nonhuman primates and occasionally in other animals. 6, 7 H. pylori infection in adults is usually chronic and will not heal without specific therapy; on the other hand, spontaneous elimination of the bacterium in childhood is probably relatively common, 8 aided by the administration of antibiotics for other reasons.
In industrialized countries, the rate of acquisition of H. pylori has decreased substantially over recent decades. Therefore, the continuous increase in the prevalence of H. pylori with age is due mostly to a cohort effect, reflecting more intense transmission at the time when members of earlier birth cohorts were children. 9 Mathematical modeling of prevalence trends in the United States has indicated that markedly improved sanitation in the second half of the 19th century greatly reduced H. pylori transmission, initiating a decline in H. pylori infection that will ultimately lead to its elimination from the U.S. population. 10 However, without intervention, H. pylori is predicted to remain endemic in the United States for at least another century. 10 Humans can also become infected with Helicobacter heilmannii, a spiral bacterium found in dogs, cats, pigs, and nonhuman primates. 11 The prevalence in humans is approximately 0.5 percent. H. heilmannii causes only mild gastritis in most cases, but it has been found in association with mucosa-associated lymphoid-tissue (MALT) lymphoma.
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Pathogenesis
The gastric mucosa is well protected against bacterial infections. H. pylori is highly adapted to this ecologic niche, with a unique array of features that permit entry into the mucus, swimming and spatial orientation in the mucus, attachment to epithelial cells, evasion of the immune response, and, as a result, persistent colonization and transmission.
The H. pylori genome (1.65 million bp) codes for about 1500 proteins. 13, 14 Among the most remarkable findings of two H. pylori genome-sequencing projects were the discovery of a large family of 32 related outer-membrane proteins (Hop proteins) that includes most known H. pylori adhesins and the discovery of many genes that can be switched on and off by slipped-strand mispairing-mediated mutagenesis. Proteins encoded by such phase-variable genes include enzymes that modify the antigenic structure of surface molecules, control the entry of foreign DNA into the bacteria, and influence bacterial motility. The genome of H. pylori changes continuously during chronic colonization of an individual host by importing small pieces of foreign DNA from other H. pylori strains during persistent or transient mixed infections. 15, 16 After being ingested, the bacteria have to evade the bactericidal activity of the gastric luminal contents and enter the mucous layer. Urease production and motility are essential for this first step of infection. Urease hydrolyzes urea into carbon dioxide and ammonia, thereby permitting H. pylori to survive in an acidic milieu. 17 The enzyme activity is regulated by a unique pH-gated urea channel, UreI, that is open at low pH and shuts down the influx of urea under neutral conditions. 18 Motility is essential for colonization, and H. pylori flagella have adapted to the gastric niche. 19 H. pylori can bind tightly to epithelial cells by multiple bacterial-surface components. 20 The best-characterized adhesin, BabA, is a 78-kD outer-membrane protein that binds to the fucosylated Lewis B blood-group antigen. 21 Several other members of the Hop protein family also mediate adhesion to epithelial cells. Accumulating evidence in animal models suggests that adhesion, particularly by BabA, is relevant in H. pylori-associated disease 22 and may influence disease severity, although the results of several studies are contradictory.
The majority of H. pylori strains express the 95-kD vacuolating cytotoxin VacA, a secreted exotoxin. 23 The toxin inserts itself into the epithelial-cell membrane and forms a hexameric anion-selective, voltage-dependent channel 24 through which bicarbonate and organic anions can be released, 24 possibly providing the bacterium with nutrients. VacA is also targeted to the mitochondrial membrane, where it causes release of cytochrome c and induces apoptosis. 25 The pathogenic role of the toxin is still debated. VacA-negative mutants can colonize in animal models, and strains with inactive vacA genes have been isolated from patients, indicating that VacA is not essential for colonization. However, VacA-negative mutants were outcompeted by wild-type bacteria in a mouse model, indicating that VacA increases bacterial fitness in this model. 26 The analysis of the role of VacA in disease is complicated by extensive variability in vacA. In Western countries, certain vacA gene variants are associated with more severe disease. 27 However, similar associations have not been found in Asia, and the functional basis underlying these associations is unknown.
Most strains of H. pylori possess the cag pathogenicity island (cag-PAI), a 37-kb genomic fragment containing 29 genes (Figure 1) . 29 Several of these encode components of a predicted type IV secretion apparatus that translocates the 120-kD protein CagA into the host cell. 30, 31 After entering the epithelial cell, CagA is phosphorylated and binds to SHP-2 tyrosine phosphatase, 32 leading to a growth factor-like cellular response and cytokine production by the host cell. Most H. pylori strains that cause disease (so-called type I strains) contain the cag pathogenicity island, a chromosomal region with about 37,000 bp and 29 genes, whose location is indicated by the arrows. The figure shows the arrangement of genes in strain 26695, whose genome sequence was the first to be published. 13 The island is split into two parts in some strains. Most of the cag genes are probably involved in the assembly of secretory machinery that translocates the protein CagA into the cytoplasm of gastric epithelial cells. Five genes (marked in orange) are similar to components of the type IV secretion system of the plant pathogen Agrobacterium tumefaciens (Vir proteins). Proteins encoded by the island are involved in two major processes, the induction of interleukin-8 production by gastric epithelial cells and the translocation of CagA from the bacterium into the host cell. All genes depicted by solid arrows are essential for the induction of interleukin-8; hatched arrows indicate genes not involved in this process. The arrows outlined in blue indicate genes required for translocation of CagA; orange lines indicate genes not essential for translocation.
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Host Response to H. pylori H. pylori causes continuous gastric inflammation in virtually all infected persons. 33 This inflammatory response initially consists of the recruitment of neutrophils, followed by T and B lymphocytes, plasma cells, and macrophages, along with epithelial-cell damage. 34 Since H. pylori rarely, if ever, invades the gastric mucosa, the host response is triggered primarily by the attachment of bacteria to epithelial cells. The pathogen can bind to class II majorhistocompatibility-complex (MHC) molecules on the surface of gastric epithelial cells, inducing their apoptosis. 35 Further changes in epithelial cells depend on proteins encoded in the cag-PAI and on the translocation of CagA into gastric epithelial cells. 30, 31 H. pylori urease and porins may contribute to extravasation and chemotaxis of neutrophils ( Figure 2 and accessory molecules B7-1 and B7-2 by epithelial cells, making them competent for antigen presentation. The cytotoxin VacA-and Fas-mediated apoptosis induced by tumor necrosis factor (TNF-) leads to disruption of the epithelial barrier, facilitating translocation of bacterial antigens and leading to further activation of macrophages. Cytokines produced by macrophages can also alter the secretion of mucus, contributing to H. pylori-mediated disruption of the mucous layer. Cytokines produced in the gastric mucosa induce changes in gastric-acid secretion and homeostasis (dashed lines). TNF-, interleukin-1 , and interferon-increase gastrin release, stimulating parietal and enterochromaffin cells and thus acid secretion. TNF-also induces a decrease in the number of antral D cells, leading to decreased somatostatin production and indirectly enhancing acid production. LPS denotes lipopolysaccharide.
The gastric epithelium of H. pylori-infected persons has enhanced levels of interleukin-1 , interleukin-2, interleukin-6, interleukin-8, and tumor necrosis factor . 38, 39, 40, 41 Among these, interleukin-8, a potent neutrophil-activating chemokine expressed by gastric epithelial cells, apparently has a central role. 39 H. pylori strains carrying the cag-PAI induce a far stronger interleukin-8 response than cag-negative strains, and this response depends on activation of nuclear factor-B (NF-B) and the early-response transcription factor activator protein 1 (AP-1). 42 In addition to the damage associated with cag-PAI-mediated translocation of proteins, H. pylori infection results in epithelial injury by several other mechanisms. Epithelial-cell damage can result from reactive oxygen or nitrogen species produced by activated neutrophils. 51 Chronic inflammation also increases epithelial-cell turnover and apoptosis, which may be due to the combined effect of direct Fas-mediated contacts between epithelial and Th1 cells and interferon-. 52 The expression levels of Fas, NF-B, and mitogen-associated protein (MAP) kinases are, in turn, regulated by interleukin-1 . Proinflammatory polymorphisms of the interleukin-1 gene favor the development of gastritis predominantly in the body of the stomach that is associated with hypochlorhydria, gastric atrophy, and gastric adenocarcinoma. In the absence of these proinflammatory polymorphisms, H. pylorimediated gastritis develops predominantly in the antrum in association with a normal to high level of acid secretion. 53 
Clinical Outcomes of Infection
The clinical course of H. pylori infection is highly variable and is influenced by both microbial and host factors (Figure 3) . The pattern and distribution of gastritis correlate strongly with the risk of clinical sequelae, namely duodenal or gastric ulcers, mucosal atrophy, gastric carcinoma, or gastric lymphoma. 54 Patients with antral-predominant gastritis, the most common form of H. pylori gastritis, are predisposed to duodenal ulcers, whereas patients with corpus-predominant gastritis and multifocal atrophy are more likely to have gastric ulcers, gastric atrophy, intestinal metaplasia, and ultimately gastric carcinoma. Gastric cancer is the second most frequent cause of cancer-related death. There is very strong evidence that H. pylori increases the risk of gastric cancer. H. pylori has been classified as a type I (definite) carcinogen since 1994, mainly on the basis of large seroepidemiologic casecontrol studies. 57, 58, 59 Additional evidence has accumulated, including results from animal models. 60 In a recent prospective study of 1526 Japanese subjects, 61 gastric cancer developed in 2.9 percent of 1246 patients with H. pylori infection over 7.8 years, whereas no gastric cancer was observed in 280 noninfected control subjects. Most important, no case of cancer was detected in a subgroup of 253 infected patients who received eradication therapy early in follow-up. The same investigators showed that eradication of H. pylori prevents relapses after endoscopic resection of early gastric cancer. 62 The results from ongoing intervention trials of the effect of H. pylori eradication on the incidence of gastric cancer may have major implications for global policies concerning the treatment and prevention of H. pylori infection.
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H. pylori
H. pylori infection significantly increases the risk of gastric MALT lymphoma, and 72 to 98 percent of patients with gastric MALT lymphoma are infected with H. pylori. 63, 64 Furthermore, eradication of H. pylori alone induces regression of gastric MALT lymphoma in 70 to 80 percent of cases. 65 Resistance of lymphoma to eradication therapy is strongly associated with certain genetic abnormalities in the host, such as the translocation t(11;18)(q21;q21), and is often associated with progression to high-grade tumors. 66 Most of the patients whose lymphomas respond to eradication therapy stay in remission for several years. 67 However, the long-term experience with patients in whom the lymphoma has been treated with antibiotics alone is still limited.
The role of H. pylori infection in dyspepsia not associated with ulcers remains controversial. An increased prevalence of H. pylori has been reported in this condition, but inconsistent long-term symptom relief has been observed with bacterial eradication in large, randomized trials. 68, 69 The reason for these discrepant results is not entirely clear. The studies showing benefit were conducted in geographic areas with a higher background of peptic ulcer disease. Subtle differences in dyspepsia-scoring systems may also have contributed to the outcome of these studies. A Cochrane review suggests that eradication of H. pylori improves symptoms in only about 9 percent of patients with dyspepsia without ulcers, but this end point may miss the other potential benefits of H. pylori eradication. 70 Eradication has become an issue in patients with gastroesophageal reflux disease, since longterm acid-suppressive therapy may aggravate H. pylori-mediated corpus gastritis and increase the risk of gastric carcinoma. 71 Conversely, some case-control and cohort studies have suggested that H. pylori infection may protect against gastroesophageal reflux disease. Two recent, fully controlled trials showed, however, that H. pylori eradication did not negatively influence relapse rates in patients with gastroesophageal reflux disease, 72, 73 but additional prospective studies are needed. Eradication of H. pylori infection in these patients makes sense in view of the risks of peptic ulcer and gastric cancer. 74 H. pylori has also been implicated in the pathogenesis of many extragastric diseases, ranging from atherosclerosis to skin diseases, but documentation is poor and the associations are controversial. 75 
Diagnostic Tests
H. pylori infection can be diagnosed by noninvasive methods or by endoscopic biopsy of the gastric mucosa; the selection of the appropriate test depends on the clinical setting. 76 Noninvasive methods include the urea breath test, serologic tests, and stool antigen assays. The urea breath test relies on the abundant, H. pylori-derived urease activity in the stomach; it qualitatively detects active infection with a sensitivity and specificity of more than 90 percent. The test is indicated for the initial diagnosis of the infection and for follow-up of eradication therapy. In the latter case, the urea breath test should not be performed before an interval of four weeks has elapsed, in order to avoid false negative results. The urea breath test is reliable in children over the age of six years but needs further validation in younger children. 77 H. pylori serologic testing is cheap and widely used for the diagnosis of H. pylori infection in patients before treatment. Although approved laboratory-based tests have sensitivity and specificity similar to those of the urea breath test, inconsistent results have been reported with some office-based tests. Because H. pylori strains differ among geographic locations, local validation is necessary. Serologic testing is of limited use in determining the success of therapy and is not reliable in young children. Stool antigen tests for H. pylori provide an alternative to the urea breath test, with a sensitivity of 89 to 98 percent and a specificity of over 90 percent. 78 Stool tests are suitable for follow-up of infection, provided that an eightweek interval is allowed after therapy. Stool tests perform well in children of all ages and may become the noninvasive method of choice for this group of patients.
Patients with alarming symptoms, such as anemia, gastrointestinal bleeding, or weight loss, as well as patients more than 50 years of age, should undergo endoscopy for the diagnosis of H. pylori infection. When endoscopy is clinically indicated, the test of first choice is a urease test on an antral-biopsy specimen. 76 It permits cheap and rapid detection of urease activity in the biopsy material, with a sensitivity of 79 to 100 percent and a specificity of 92 to 100 percent. 78 Sensitivity can be improved by additional biopsies, but false negative results are observed in patients with active or recent bleeding and in patients taking antibiotics or antisecretory compounds. If the urease test is negative, additional biopsy specimens stored in fixative can be sent for histologic examination. Culture of H. pylori with antibiotic-sensitivity testing is not routinely performed for the initial diagnosis of H. pylori infection, but it is recommended after the failure of second-line therapy. 79 Guidelines for performing antibiotic-susceptibility tests of H. pylori have been developed by the National Committee for Clinical Laboratory Standards. 80 
Treatment of H. pylori Infection
The goal of H. pylori treatment is the complete elimination of the organism. Once this has been achieved, reinfection rates are low; thus, the benefit of treatment is durable. Clinically relevant H. pylori-eradication regimens must have cure rates of at least 80 percent (according to intention-to-treat analysis) without major side effects and with minimal induction of bacterial resistance. Such goals have not been achieved with antibiotics alone. Because luminal acidity influences the effectiveness of some antimicrobial agents that are active against H. pylori, antibiotics are combined with proton-pump inhibitors or ranitidine bismuth citrate. So-called triple therapies, combinations of one antisecretory agent with two antimicrobial agents for 7 to 14 days, have been extensively evaluated, and several regimens have been approved by the Food and Drug Administration (FDA) ( Table 1) . The combination of two or more antimicrobial agents increases rates of cure and reduces the risk of selecting for resistant H. pylori. The chief antimicrobial agents used in these regimens are amoxicillin, clarithromycin, metronidazole, tetracycline, and bismuth. Primary resistance to amoxicillin and tetracycline remains uncommon, but the frequency of clarithromycin resistance is now around 10 percent in most European countries and the United States and even higher in Japan. 81 Metronidazole resistance ranges between 20 percent and 30 percent and is more frequent among women and among both men and women in developing countries, because of the frequent use of nitroimidazoles to treat other diseases. 81 Resistance of H. pylori to macrolides is caused by point mutations in the 23S ribosomal RNA genes. Resistance to metronidazole is caused primarily by mutations in nitroreductase genes (rdxA and frxA) that interfere with the intracellular activation of nitroimidazoles. 
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First-Line Therapies
Proton-Pump-Inhibitor-Based Triple Therapies
Following the success of initial trials of proton-pump-inhibitor-based triple therapy in Italy and France, large, randomized trials confirmed the effectiveness of treatment twice daily for seven days with 20 mg of omeprazole, given either with 1 g of amoxicillin and 500 mg of clarithromycin, or with 400 mg of metronidazole and 250 mg of clarithromycin. 83, 84, 85, 86 Several comparative trials have demonstrated the equivalence of 30 mg of lansoprazole twice daily, 40 mg of pantoprazole twice daily, 20 mg of rabeprazole daily, and 20 mg of esomeprazole twice daily with omeprazole in these triple therapies. 87, 88, 89, 90 In a meta-analysis of 666 studies that included 53,228 patients, combinations of a protonpump inhibitor, clarithromycin, and a nitroimidazole; a proton-pump inhibitor, clarithromycin, and amoxicillin; and a proton-pump inhibitor, amoxicillin, and a nitroimidazole were judged to be similar, with rates of cure of 78.9 to 82.8 percent according to intention-to-treat analyses. 91 Increasing the dose of clarithromycin to 1.5 g per day improved rates of cure, but increasing the doses of the other antibiotics did not. In another pooled analysis, no effect of larger doses of proton-pump inhibitors was observed among the triple therapies. 92 The duration of therapy remains controversial. In Europe, 7-day treatment is recommended, 79 whereas in the United States, 14-day courses have been found to be better than shorter courses and are approved by the FDA. In a recent meta-analysis, 14-day treatment achieved rates of cure 7 to 9 percentage points better than 7-day treatment. 93 Primary resistance to clarithromycin and metronidazole decreases rates of cure by 50 percent and 37 percent, respectively. 94 The indication for therapy, bacterial factors, patient compliance, and geographic differences can further affect rates of cure.
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Ranitidine Bismuth Citrate-Based Therapies
Ranitidine bismuth citrate in dual therapy with clarithromycin for two weeks has been approved by the FDA. 96 Meta-analyses suggest that ranitidine bismuth citrate with clarithromycin and amoxicillin, or with clarithromycin and a nitroimidazole, performs as well as corresponding proton-pump-inhibitor-based therapies. 91, 97 Ranitidine bismuth citrate-based regimens may be less influenced by antibiotic resistance than their proton-pump-inhibitorbased counterparts. 98, 99 No ranitidine bismuth citrate-based triple therapy has been approved by the FDA.
Bismuth-Based Triple Therapies
Bismuth in association with metronidazole and tetracycline compares well in meta-analyses with therapies based on proton-pump inhibitors or ranitidine bismuth citrate, even if the duration of treatment is reduced to seven days. 91, 98 This inexpensive regimen remains an important option. Efficacy is negatively affected by metronidazole resistance. 98 Furazolidone, a nitrofuran derivative, has also been proposed for use in bismuth-based triple therapies. Triple therapy for two weeks, consisting of 100 mg of furazolidone four times daily, amoxicillin, and bismuth, was successful in 86 percent of cases. However, furazolidone, particularly when combined with bismuth for two weeks, is associated with substantial side effects. Standard bismuth-based therapy and its furazolidone-containing alternatives were recommended at the 1999 Latin American Consensus Conference. 100 Three regimens were recommended by the 1998 U.S. Consensus Conference 76 : a proton-pump inhibitor, clarithromycin, and either amoxicillin or metronidazole for two weeks; ranitidine bismuth citrate, clarithromycin, and amoxicillin, metronidazole, or tetracycline for two weeks; and a proton-pump inhibitor, bismuth, metronidazole, and tetracycline for one to two weeks. The regimens recommended by the European Maastricht 2-2000 79 conference are a protonpump inhibitor (or ranitidine bismuth citrate), clarithromycin, and amoxicillin or metronidazole for seven days. Because there are insufficient data for the pediatric age group, no treatment regimen for children infected with H. pylori was recommended by the European Paediatric Task Force. 77 FDA-approved regimens are listed in Table 1 .
Second-Line Therapies
Eradication is more difficult when a first treatment attempt has failed, usually because of either poor patient compliance or the development of antibiotic resistance. Therefore, a 10-to-14-day treatment course is advocated for second-line therapies. However, the optimal strategy for retreatment after the failure of eradication has not yet been established.
Because the failure of therapy is often associated with secondary antibiotic resistance, retreatment should ideally be guided by data on susceptibility. However, such information is often unavailable, so quadruple therapies, in which a proton-pump inhibitor or an H 2 -receptor antagonist is added to a bismuth-based triple regimen with high-dose metronidazole, have been suggested as optimal second-line therapy. According to a recent meta-analysis, the pooled eradication rate in 30 trials in which this strategy was tested was 76 percent. 101 This second-line therapy was recommended at major consensus conferences, 79, 102 although it may prove disappointing, given the failure of regimens containing metronidazole. 101 Another approach to retreatment without susceptibility testing is to prescribe a second course of proton-pump-inhibitor-based triple therapy, avoiding antimicrobial agents against which prior therapy may have induced resistance and avoiding less effective combinations, such as amoxicillin and tetracycline. If a clarithromycin-based regimen is used first, a metronidazolebased regimen should be used afterward, or vice versa. This concept is supported by pooled analysis, 101 but prospective studies of consecutive combinations of triple therapies are needed. Alternative approaches to second-line proton-pump-inhibitor-based therapies have been reported recently, but mostly in abstract form. Rifabutin, given in association with amoxicillin and pantoprazole for 10 days, achieved an 86 percent rate of cure, even in patients with resistant strains. 103 In a pooled analysis of nine studies, retreatment with ranitidine bismuth citrate-based triple therapy yielded an 80 percent rate of cure, 101 similar to the rates with quadruple therapies; and in a recent randomized trial, ranitidine bismuth citrate, clarithromycin, and tinidazole achieved an 81 percent rate of cure after the failure of triple therapies based on proton-pump inhibitors. 104 In locations where ranitidine bismuth citrate is available, triple therapies based on this compound can be used for second-line treatment.
Indications for Therapy
The National Institutes of Health Consensus Development Conference in 1994 was the first to propose generalized guidelines for the management of H. pylori infection. These guidelines were updated in 1997, but the most recent U.S. guidelines were prepared in 1998 by the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. 76 Testing for H. pylori is recommended only if treatment is intended. Primary indications for such testing and subsequent treatment include active peptic ulcer disease, a history of documented peptic ulcer, or gastric MALT lymphoma. Testing of patients with nonulcer dyspepsia may be performed on a case-by-case basis, but it is not indicated in asymptomatic patients or in patients receiving long-term treatment with a proton-pump inhibitor for gastroesophageal reflux disease. No recommendations were issued for patients receiving only nonsteroidal antiinflammatory drugs (NSAIDs).
The recommendations issued by the more recent European Maastricht 2-2000 panel are organized in two levels and are presented in Table 2 . 79 Canadian and Asia-Pacific guidelines correspond largely to the Maastricht 2-2000 guidelines. The European Paediatric Task Force identified gastric and duodenal ulcer disease as indications for therapy in children. This panel agreed that there is no specific clinical picture associated with H. pylori in children, and that the benefit of H. pylori eradication in children with dyspepsia has not been established. Therefore, in children, testing for H. pylori is recommended only if the symptoms are severe enough to justify therapy. In populations with a high prevalence of H. pylori, routine screening would lead to the treatment of large numbers of children, with no demonstration of benefits as compared with risks and costs, because H. pylori-related ulcer disease is much less frequent in children than in adults and because therapy for the prevention of other consequences of the infection can be postponed. Several issues regarding indications for therapy remain unresolved. The available results suggest that subgroups of patients with nonulcer dyspepsia may benefit from the eradication of H. pylori infection, but clear criteria for the identification of these subgroups are lacking.
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In dyspeptic patients who have not been evaluated by endoscopy, however, testing for H. pylori and treating patients with positive findings may be as effective as endoscopy-based management and may reduce costs. 105 The precise contribution of H. pylori to ulcerogenesis and to upper intestinal bleeding in users of NSAIDs remains unclear. Finally, the risk of cancer may be high in patients with nonulcer dyspepsia. 61 Although more studies are needed to confirm these results, it can be argued that H. pylori infection should be treated in these patients on the basis of the risk of cancer alone.
Perspective
H. pylori continues to be one of the most common bacterial infections in humans. Functional genomics may fill many of the gaps in our understanding of the pathogenesis of H. pylori infection and accelerate the development of novel therapies, including H. pylori-specific antimicrobial agents. Although enormous progress has been made in studying the virulence factors of H. pylori and their variation, this information has not yet been used in clinical practice. Associations between bacterial characteristics and disease risks have not yet been defined sufficiently well to guide the clinician in treatment decisions. Prophylactic and therapeutic vaccination have been successful in animal models, but the translation to a human vaccine remains difficult, in part because the immunology of the stomach is still poorly understood. 106, 107 All of these developments will probably be needed to prevent and treat this infection in areas of the world where there is a high prevalence of chronic infection.
